Kristen Britton

Kristen Britton

Auto-generated profile, based on publicly available information

Kristen Britton

United States Food and Drug Administration, Silver Spring, MD, United States

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
KBKristen Britton
Kristen Britton
UMUpendra Mahat
Upendra Mahat
NRNicholas C. Richardson
Nicholas C. Richardson
MTMillion Adane Tegenge
Million Adane Tegenge
QGQianmiao Gao
Qianmiao Gao
LFLola A. Fashoyin-Aje
Lola A. Fashoyin-Aje
In May 2024, the FDA granted accelerated approval to lisocabtagene maraleucel for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. The single-arm, open-label, multicenter, phase 2 TRANSCEND-FL trial evaluating a single dose of lisocabtagene maraleucel in adults with R/R indolent non-Hodgkin lymphoma supported the FL indication. The trial enrolled 139 patients with R/R FL, including 107 with two or more prior lines of therapy. Of the 107 patients, 94 patients comprised the primary efficacy population and the independent review committee-assessed overall response rate was 95.7% (95% confidence interval [CI]: 89.5, 98.8), with 73.4% (95% CI: 63.3, 82.0) achieving complete response. The median duration of response was not reached (95% CI: 18.0 months, NR) and the 1-year remission rate was 81% (95% CI: 71, 88). Serious adverse reactions occurred in 26% of patients, most often due to cytokine release syndrome (CRS), neurologic toxicity, and febrile neutropenia. CRS occurred in 59% (Grade 3: 1%) of patients and neurologic toxicities occurred in 15% (Grade 3: 2%). As a condition of accelerated approval, post marketing studies were required to verify the clinical benefit of lisocabtagene maraleucel in R/R FL. This article summarizes key aspects of the regulatory review.